GITR agonist enhances vaccination responses in lung cancer

OncoImmunology

Volumn 4, Issue 4, 2015, Pages

  Zhu, Li X ^a,b   Davoodi, Michael ^b   Srivastava, Minu K ^a,b   Kachroo, Puja ^a   Lee, Jay M ^a,b   John, Maie St ^a   Harris White, Marni ^b   Huang, Min ^a,b   Strieter, Robert M ^c   Dubinett, Steven ^a,b   Sharma, Sherven ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

APC; Lung cancer; NK; T cell activation; Vaccination responses

Indexed keywords

CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CARCINOGENESIS; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FOLDING; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REJECTION; TUMOR VOLUME; VACCINATION REACTION;

EID: 84954349721     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.992237     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Ca; 63:11-30; PMID:23335087
2. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005
3. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6:1755-66; PMID:10815894
4. Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett SM, Sharma S. Role of CXCR3 ligands in IL-7/IL-7R{alpha}-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res 2011; 17:3660-72; PMID:21636553; http://dx. doi. org/10. 1158/1078-0432. CCR-10-3346
5. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, Jeffrey RR. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000; 27:27-35; PMID:10672781; http://dx. doi. org/10. 1016/S0169-5002(99)00095-1
6. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in nonsmall-cell lung carcinoma. Br J Cancer 2006; 94:275-80; PMID:16421594; http://dx. doi. org/10. 1038/sj. bjc. 6602934
7. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx. doi. org/ 10. 1200/JCO. 2007. 15. 0284
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx. doi. org/10. 1056/NEJMoa1003466
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx. doi. org/10. 1056/NEJMoa1200690
10. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx. doi. org/ 10. 1056/NEJMoa1104621
11. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3:135-42; PMID:11812990; http://dx. doi. org/10. 1038/ni759
12. Nocentini G, Riccardi C. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 2005; 35:1016-22; PMID:15770698; http://dx. doi. org/10. 1002/ eji. 200425818
13. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E, Riccardi C. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004; 34:613-22; PMID:14991590; http:// dx. doi. org/10. 1002/eji. 200324804
14. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, Shevach EM. Engagement of glucocorticoid-induced TNFR familyrelated receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004; 173:5008-20; PMID:15470044; http://dx. doi. org/10. 4049/jimmunol. 173. 8. 5008
15. Esparza EM, Arch RH. Glucocorticoid-induced TNF receptor, a costimulatory receptor on naive and activated T cells, uses TNF receptor-associated factor 2 in a novel fashion as an inhibitor of NF-kappa B activation. J Immunol 2005; 174:7875-82; PMID:15944293; http://dx. doi. org/10. 4049/ jimmunol. 174. 12. 7875
16. Esparza EM, Arch RH. Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J Immunol 2005; 174:7869-74; PMID:15944292; http://dx. doi. org/10. 4049/jimmunol. 174. 12. 7869
17. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867
18. Shastri N, Gonzalez F. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J Immunol 1993; 150:2724-36; PMID:8454852
19. McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocytemonocyte colony-stimulating factor, and interferongamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol 1995; 165:183-92; PMID:7553882; http:// dx. doi. org/10. 1006/cimm. 1995. 1204
20. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 2009; 182:6951-8; PMID:19454692; http://dx. doi. org/10. 4049/jimmunol. 0803340
21. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. NK cells and cancer. J Immunol 2007; 178:4011-6; PMID:17371953; http://dx. doi. org/10. 4049/jimmunol. 178. 7. 4011
22. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 2007; 26:798-811; PMID:17540585; http://dx. doi. org/10. 1016/j. immuni. 2007. 04. 010
23. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, Dubinett SM. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163:5020-8; PMID:10528207